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ABSTRACT A heat-labile Epstein-Barr virus-specific
DNA polymerase stimulatory protein having a molecular mass
of 45 kDa was purified from phorbol 12-myristate 13-acetate-
treated P3HR-1 cells by column chromatography. The virus
DNA polymerase stimulatory protein was precipitated by sera
from patients with nasopharyngeal carcinoma but not by sera
from healthy donors. The interaction of the stimulatory protein
with DNA polymerase was stoichiometric. Furthermore, this
protein stimulated Epstein-Barr virus DNA polymerase but
not herpes simplex virus type 1 or type 2 or human DNA
polymerase a. The stimulatory protein did not alter the Km
value of dTTP or DNA but did increase the Vn. of DNA
polymerase. Salt concentrations between 100mM and 150mM
KCI were optimal for this protein-induced stimulation of
Epstein-Barr virus DNA polymerase activity. The presence of
the stimulatory protein in the reaction mixture enhanced the
sensitivity of virus DNA polymerase to phosphonoformate.
There are five types of herpesviruses that induce human
disease. Among these, Epstein-Barr virus (EBV) is known to
have close association with Burkitt lymphoma and nasophar-
yngeal carcinoma (NPC) (1). The EBV genomes present in
both virus-infected and virus-carrying cells (2) are able to
induce several virus-specified proteins. It has been shown
that EBV induces a virus-specified DNA polymerase and
DNase (3-6). The activities of both enzymes increase when
EBV-carrying cells, P3HR-1 cells, are treated with the
tumor-promoting ester phorbol 12-myristate 13-acetate
(PMA) (3, 7). Procedures to highly purify EBV DNA poly-
merase by various column chromatographic techniques have
been described (3, 7-10). Based on our experience, recovery
ofthe enzyme activity is poor and quite inconsistent through-
out the purification. This raises the question of whether the
loss of enzyme activity during purification is the result of the
separation of a stimulatory protein from the enzyme or is due
to instability of the enzyme. This communication describes
the purification and some properties ofan EBV-specific DNA
polymerase stimulatory protein.
MATERIALS AND METHODS
Chemicals. All chemicals were of reagent grade or better.
Unlabeled dNTPs, calf thymus DNA, dithiothreitol, bovine
serum albumin, phenylmethylsulfonyl fluoride, and PMA
were obtained from Sigma. ICN was the source of [3H]dTTP.
Phosphonoformate was a gift from Astra A.B. (Sodertalje,
Sweden). NPC patient sera used for immunostaining were
provided by Tseng-Chou Lynn from the National Taiwan
University Hospital.
Treatment of P3HR-1 Cells with PMA. The EBV-producer
cell line P3HR-1 was maintained at 370C in humidified 5%
C02/95% air. The P3HR-1 cells were grown as a stationary-
phase suspension culture in RPMI 1640 medium containing
10% fetal calf serum. For the induction of virus-specified
proteins, cells seeded at a density of 5 x 105/ml were grown
as suspension cultures for 6 days at 34TC. The cells were then
pelleted and suspended in fresh medium containing PMA at
40 ng/ml. After a 4-day incubation, the cells were collected
by centrifugation and stored at -70'C until use.
Preparation of Viral and Human DNA Polymerases. EBV-
specified DNA polymerase from PMA-treated P3HR-1 cells
was purified as described (3). This involved DEAE-cellulose,
phosphocellulose, and DNA-cellulose column chromatogra-
phy. The final specific activity ofEBV DNA polymerase was
>4.0 x 105 units (defined below) per mg of protein. Herpes
simplex virus (HSV) type 1 and type 2 DNA polymerases
were purified from HSV-1 (KOS strain)- and HSV-2 (333
strain)-infected HeLa cells, respectively, as described (11,
12). Human DNA polymerase a was purified from HeLa cells
by a published procedure (12).
DNA Polymerase Assay. The reaction mixture for the assay
of different types of DNA polymerase was the same except
for the concentration of KCl. The mixture (100 ILI) was
composed of 50 mM Tris-HCl, pH 8.0/4 mM MgCl2/0.5 mM
dithiothreitol/0. 1 mM dATP/0. 1 mM dGTP/0.1 mM dCTP/5
,uM [3H]dTTP (40 mCi/,tmol; 1 Ci = 37 GBq) containing
bovine serum albumin at 0.2 mg/ml, 15 ,ug of activated calf
thymus DNA, and different amounts of KCl. For EBV,
HSV-1, HSV-2, and human DNA polymerase a, the concen-
trations of KCl were 150, 200, 200, and 0 mM, respectively.
One unit of enzyme activity is defined as the amount of
enzyme that catalyzes the incorporation of 1 pmol of dTMP
into activated DNA per min at 370C as described (12).
Electrophoresis, Blotting, and Immunostaining. NaDod-
S04/polyacrylamide gel electrophoresis was carried out
according to Laemmli (13) using 10% gels. After electropho-
resis, slab gels were silver stained following the method of
Merril et al. (14). Proteins were transferred to nitrocellulose
paper according to the method of Bowen et al. (15). Im-
munostaining of proteins on nitrocellulose paper was carried
out according to Legochi and Verma (16).
Serological Test. Immunoprecipitation of EBV DNA poly-
merase stimulatory protein was accomplished by adding
diluted (1:5) NPC patient serum or control serum from
healthy individuals. After incubation at room temperature for
20 min, 10 ,lI of previously swollen protein A-conjugated
Sepharose (Pharmacia) was added. After further incubation
for 1 hr at 4°C, the immunocomplexes were pelleted by
Abbreviations: EBV, Epstein-Barr virus; PMA, phorbol 12-
myristate 13-acetate; HSV, herpes simplex virus.
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centrifugation and the supernatant was examined for DNA
polymerase stimulatory protein activity using purified EBV
DNA polymerase.
RESULTS
Demonstration and Purification of EBV DNA Polymerase
Stimulatory Protein. A crude homogenate of PMA-treated
P3HR-1 cells was passed first through a DEAE-cellulose
column to remove nucleic acid and then through a second
DEAE column for further purification (3). EBV DNA poly-
merase having a total apparent activity of 5.7 x 103 units was
then loaded onto a phosphocellulose column. This column
was developed with a linear gradient of 50-400 mM phos-
phate buffer that contained 20% glycerol/i mM EDTA/1 mM
phenylmethylsulfonyl fluoride/2 mM dithiothreitol. Frac-
tions of 3.4 ml were collected and 10 Al of each was assayed
for DNA polymerase activity with and without 0.2 unit of
purified EBV DNA polymerase preparation (after DNA-
cellulose column chromatography). The results are shown in
Fig. LA. The recovery of apparent DNA polymerase (frac-
tions 45-55) was -10%. There was a factor in several
fractions that eluted ahead of the EBV DNA polymerase
activity peak and stimulated added EBV DNA polymerase.
Those fractions (tubes 36-39) were pooled and applied to a
DNA-cellulose column (0.8 x 2 cm), which was developed
with a linear 50-400 mM phosphate gradient. The elution
profile for the stimulatory factor is shown in Fig. 1B. The
peak fractions (tubes 19-21, 2.5-ml fractions) were pooled
and applied to a heparin-Sepharose column (0.8 x 1.5 cm).
This column was developed with a linear 100-400 mM
phosphate gradient. The elution profile for the stimulatory
protein from this column is shown in Fig. 1C. The concen-
tration of protein in these peak fractions (1.0 ml each) was <1
,ug/ml. There was no intrinsic DNA polymerase activity. To
assess the purity of the protein(s) in the peak fraction (tube
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FIG. 1. Column chromatography profiles of the EBV DNA
polymerase stimulatory protein. (A) The cellular extract (5 x 109
cells) was passed through a DEAE-cellulose column as described (3)
and then loaded onto a phosphocellulose column. (B) The peak
fraction from the phosphocellulose column was loaded onto a
single-stranded DNA-cellulose column. (C) The peak fraction from
the DNA-cellulose column was purified on a heparin-Sepharose
column. The amount ofEBV DNA polymerase used for detecting the
activity of the stimulatory protein was 0.1 unit per assay (e). o,





FIG. 2. Electrophoresis profiles of the final preparation of the
stimulatory protein. After purification through the heparin-Seph-
arose column chromatography step, the stimulatory protein was
electrophoresed as described (17). Slab gels were either silver stained
(lane A) or transferred to nitrocellulose paper and immunostained by
a technique using serum from a NPC patient (lane B). The amount of
activator shown here caused maximal stimulation of at least 1 unit of
EBV DNA polymerase, which is equivalent to 100 Al of the
stimulatory protein preparation described in Fig. 3.
silver- or immunostaining (Fig. 2). One major protein band
was detected by the silver-staining technique (Fig. 2, lane A).
One protein with an apparent molecular mass of 45 kDa was
recognized by serum from patients with NPC (Fig. 2, lane B)
but not by serum from normal individuals (data not shown).
Occasionally, a 98-kDa protein was also immunostained.
Presence of Antibodies Against the Stimulatory Protein in
Sera of Patients with Nasopharyngeal Carcinoma. To further
substantiate that the protein band that could be stained on
nitrocellulose paper was the stimulatory protein, the stimula-
tory protein was mixed with sera from NPC patients or from
normal individuals for 20 min at room temperature. To each
protein A-conjugated Sepharose was added as described.
Immunocomplexes were pelleted by centrifugation after 1 hr
of incubation at 4°C. The supernatant was assayed for the
presence of this protein and the results are shown in Table 1.
The stimulatory protein was immunoprecipitated by sera
from NPC patients but not by sera from normal individuals.
Since the sera from NPC patients stained only one protein on
the nitrocellulose sheet after immunological blotting, the
protein band observed in Fig. 2 (lane B) with a molecular
mass of 45 kDa could be the stimulatory protein.
Interaction of the Stimulatory Protein and DNA Polymerase.
Different amounts of the stimulatory protein were added to a
fixed amount (0.2 unit) ofEBV DNA polymerase. The degree
of activation reached a plateau with a maximum degree of
activation of about 8-fold (Fig. 3B). This varied depending on
the degree of contamination of the protein in the DNA
polymerase preparation used. With a fixed amount of the
stimulatory protein, different amounts of enzyme were add-
ed, and a marked stimulation was observed at a low concen-
tration of enzyme (<0.6 unit). No further stimulation was
observed when more enzyme was added (Fig. 3A). Thus, the
results shown in Fig. 3 indicate a stoichiometric interaction
of activator and DNA polymerase.
The specificity of the stimulatory protein toward various
types ofDNA polymerase was examined, and the results are
shown in Table 2. The amount of activator that gave a 4-fold
stimulation of EBV DNA polymerase did not stimulate
HSV-1, HSV-2, or human DNA polymerase a.
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Table 1. Interaction of the stimulatory protein with sera of
nasopharyngeal carcinoma patients or normal individuals
Stimulatory





The stimulatory protein (the amount capable of fully stimulating
0.01 unit of EBV DNA polymerase) was incubated with an equal
volume of diluted (1:5) NPC patient sera or normal healthy individual
sera for 20 min at room temperature and then added to 10 /LI of
previously swollen protein A-Sepharose and incubated for 1 hr at
40C. The mixture was centrifuged, and 10 1.d of supernatant was
assayed for the remaining stimulatory protein in (total volume, 0.1
ml) 150 mM KCI/50 mM Tris HCl, pH 8.0/4 mM MgCl2/0.5 mM
dithiothreitol/0.1 mM dATP/0.1 mM dCTP/0.1 mM dGTP/5 ,uM
[3H]dTTP (40 ,Ci/ml) containing bovine serum albumin at 0.2
mg/ml, 15 ug of activated calf thymus DNA, and 0.01 unit of EBV
DNA polymerase. After 20 min of incubation at 37°C, 50-,ul aliquots
were spotted onto GF/A filters and the filters were washed with cold
5% trichloroacetic acid and 1 mM sodium pyrophosphate to deter-
mine acid-insoluble radioactivity. Results presented are ranges of
values obtained with six individual sera. The stimulatory protein
control was treated in the same fashion except that phosphate-
buffered saline was used in place of sera in the first incubation.
Effect of the Stimulatory Protein on the Kinetic Behavior of
DNA Polymerase. The effect of the stimulatory protein on the
Km and Vmax of EBV DNA polymerase was examined, and
typical results are shown in Fig. 4. This protein did not alter
the Km of the enzyme for dTTP or DNA but it did increase
the Vma of DNA polymerase.
Effect on the Behavior ofDNA Polymerase Toward Salt and
Phosphonoformate. Salt is known to stimulate EBV DNA
polymerase with an optimal concentration between 100 mM
and 150 mM KCl. Addition of the stimulatory protein did not
alter the profile in a qualitative sense but did alter it in a
quantitative sense (Fig. 5A). When the effect of phosphono-
formate on EBV DNA polymerase was tested in the presence
and absence of the amount of stimulatory protein that gave
maximum stimulation, the stimulatory protein enhanced the
sensitivity of the polymerase (Fig. 5B).
Heat Stability of the Activator. Heat inactivation of the
EBV DNA polymerase stimulatory protein is shown in Fig.
6. The stimulatory effect of this protein on EBV DNA
polymerase was decreased by 60%G after incubation for 10 min
at 65°C. Further incubation resulted in continued inactivation
of the stimulatory protein.
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FIG. 3. Interaction of the stimulatory protein and EBV DNA
polymerase. Reactions were carried out with a variable amount of
DNA polymerase and either a fixed amount (2.5 ,ul) ofthe stimulatory
protein (o) or no stimulatory protein (o) (A) or with a fixed amount
(0.2 unit) of EBV DNA polymerase and a variable amount of the
stimulatory protein (B).
Table 2. Specificity of the stimulatory protein toward
DNA polymerase
cpm
DNA polymerase Without SP With SP




Ten microliters of the stimulatory protein (SP) described in Fig. 3
was used per assay mixture.
DISCUSSION
A specific EBV DNA polymerase stimulatory protein having
an apparent molecular mass of 45 kDa has been found. This
protein could be separated from EBV DNA polymerase by
phosphocellulose column chromatography. This may at least
partly explain why the yield of the apparent EBV DNA
polymerase activity through this purification step varies from
one preparation to another. The interaction of EBV DNA
polymerase and its stimulatory protein is apparently
stoichiometric. Upon PMA induction ofEBV DNA polymer-
ase activity in P3HR-1 cells, the relative amounts of the
stimulatory protein and EBV DNA polymerase did not
change. We have not fractionated a homogenate from
uninduced cells but we did add a purified polymerase (the
preparation after the DNA-cellulose step) to such a
homogenate and observed only additive activity. Similarly,
addition of purified stimulatory protein did not increase the
activity of the homogenate from uninduced cells. Concurrent
induction of the stimulatory protein and polymerase is
indicated. It is possible that this protein is an integral part of
EBV DNA polymerase and that the catalytic portion of the
enzyme becomes dissociated from the stimulatory protein or
proteolysis during the purification separates these proteins.
This will require further investigation. It can be concluded
that the interaction of this protein with EBV DNA polymer-
ase is quite specific. It should be stated that, in the purified
stimulatory protein preparation, there was no detectable
DNA topisomerase or DNA endo- or exonuclease activity
using the assay procedure described in refs. 18-20. The
1/dTTP, ,M-'
FIG. 4. Effect of the stimulatory protein on the kinetic properties
of EBV DNA polymerase. Data for Lineweaver-Burk plots were
obtained by varying the concentration of either [3H]dTTP (A) or
activated calf thymus DNA (B) with (o) or without (o) addition of the
stimulatory protein (5 ,ul as described in Fig. 2) and using 0.2 unit of
EBV DNA polymerase. The reaction time was 20 min at 37°C.
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FIG. 5. Effect of the stimulatory protein on the salt (A) and
phosphonoformate (B) sensitivities of EBV DNA polymerase. Stud-
ies were performed with (e) or without (o) added stimulatory protein,
which caused a 6-fold activation of 0.1 unit ofEBV DNA polymerase
and was equivalent to S ,ul of the preparation described in Fig. 3. The
amount of EBV DNA polymerase used was 0.2 unit. The KCl
concentration used in B was 150 mM.
detailed mechanism of DNA polymerase activation by this
protein is still unclear.
The appearance of two peaks of EBV DNA polymerase
activity in the final purification step (DNA-cellulose column
chromatography) has been reported (3). These two peaks of
activity were stimulated by salt to different extents and had
different sensitivities to phosphonoformate, a potent DNA
polymerase inhibitor. In this work, by careful separation of
the stimulatory protein from DNA polymerase on a
phosphocellulose column, only one peak ofDNA polymerase
was observed in the final purification step. In this commu-
nication we have reported that stimulatory protein alters the
KCI concentration dependence and the phosphonoformate
sensitivity of EBV DNA polymerase. It is likely that the
observation of two peaks of activity at the DNA-cellulose
column step was due to the presence of the stimulatory
protein in one of those peaks. This may also provide an
explanation for the differences in the properties ofEBV DNA
polymerase observed by different investigators.
A higher titer of antibodies against EBV DNase was found
in sera from patients with NPC than in sera from normal
individuals (21, 22). Antibodies against the EBV DNA
polymerase stimulatory protein were also found in sera from
Incubation time, min
FIG. 6. Stability of the stimulatory protein at 650C. Purified
stimulatory protein was incubated at 650C in 100 mM potassium
phosphate (pH 7.5) for the times indicated. The stimulatory protein
was assayed by examining its ability to stimulate DNA polymerase
(0.2 unit). The protein initially used (5 /.d as described in Fig. 3) could
not stimulate more than 0.2 unit of DNA polymerase.
patients with NPC and not in sera from normal individuals.
Whether sera from patients with NPC have a higher frequen-
cy and higher titer of antibodies against EBV DNA polymer-
ase activator than sera from normal individuals is not known.
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